Background: Angiogenesis stands as a symbol for the development of tumor
as well as its metastasis. In this review, we discuss the various components that induce
and enhance angiogenesis along with its several inhibitors in neuroblastoma. Angiogenesis
is vital for tumor development and migration and it is dependent on the creation
of angiogenic elements by tumor cell lines.
Methodology: Neuroblastoma (NB) is a general pediatric tumor which originates from
neural crest that is biologically and physiologically diverse. As tumor vascular index increases,
it leads to the unfavorable consequence of NB. Tumor vascularity is very much
interrelated with an ill consequence of neuroblastoma. Hence, unique drugs which aim
at the vascular endothelium are applicants for integration into clinical experimentation.
As the quest for new anti-angiogenic compounds goes on, several angiogenic inhibitors
get discovered whose progress needs to be scrutinized from time to time. Antiangiogenic
activity of a drug gets elevated when used as combination therapy than
monotherapy. Vascular targeting is yet another strategy to increase the efficacy of antiangiogenic
therapy. In general for children having neuroblastoma, the anti-angiogenic
therapy works as a boon when administered along with gene therapy.
Results: As a resulting discovery of unique molecular objective, several inhibition mediators
are gaining attention of exploration by neuroblastoma researchers. The further
discussion proceeds with understanding the process of angiogenesis, its clinical inferences,
and future perspectives. Novel and more efficient methodologies are required to
diagnose and treat extremely antagonistic neuroblastoma.